GB2514863A - A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin - Google Patents

A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin Download PDF

Info

Publication number
GB2514863A
GB2514863A GB1318577.2A GB201318577A GB2514863A GB 2514863 A GB2514863 A GB 2514863A GB 201318577 A GB201318577 A GB 201318577A GB 2514863 A GB2514863 A GB 2514863A
Authority
GB
United Kingdom
Prior art keywords
solution
volume
use according
glycerin
certain percentage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1318577.2A
Other versions
GB201318577D0 (en
Inventor
Thomas Benedict Bryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/912,060 external-priority patent/US9549904B2/en
Application filed by Individual filed Critical Individual
Publication of GB201318577D0 publication Critical patent/GB201318577D0/en
Publication of GB2514863A publication Critical patent/GB2514863A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A normal saline solution comprising glycerin and amino acids is disclosed for use in the prevention or inhibition of biofilm formation by a population of bacteria. The concentration of glycerin in the normal saline solution may be 3% by volume, whilst the concentration of amino acids in the normal saline solution may be 3% by volume. In some embodiments, the intravenous solution is administered for 48 hours at 80 cc/hour. The solution may also be infused via intracavernous administration into an infected body cavity.

Description

A METHOD OF DESTROYING BACTERIAL BIOFILM USING STERILE
INTRAVENOUS OR INTRACAVERNOUS GLYCERIN
BACKGROUND OF THE INVENTION
[00011 Field of Invention
[00021 This invention pertains to the use of sterile intravenous or intracavemous glycerin solutions to treat biofilms that infect humans and animals.
[00031 Description of Related Art
[00041 A biofllm occurs when bacteria stick to each other on a surface. These adherent cells are frequently embedded within a self-producing matrix of extra eel lular polymeric substance. Biofilms are also referred to as slime. The polymeric conglomeration is generally composed of extra-cellular DNA, proteins and polysaceharides. Initially the biofilm is weak and adhesion is by yan der Waals forces. Later, the bacteria form cell adhesion structures such as pili. Once colonization has begun the biofilm grows through a combination of cell division and recruitment.
[0005] The development of biofilm may allow for an aggregated cell colony to be increasingly antibiotic resistant. Bacteria from the biofilm can disperse which causes the spread and colonization of new surfaces. The matrix protects the bacteria within it and facilitates communication among them through biochemical signals. Biofilm has been implicated in such problems as urinary tract infections, endocarditis, cystic fibrosis and infections of prosthesis and heart valve. Invariably the only recourse for treating prosthetics such as mechanical heart valve is to have them replaced. Biofilms are present on the removed tissue of 80% of patients undergoing surgery for chronic sinusitis.
[0006] In the 1980's Danish pioneers first connected biofilms with human disease and then antibiotic resistant infections. They discovered that once these biofilm infections had begun they are difficult to get rid of in the body. The immune system can mop up free-floating bacteria in the blood but reaching bacteria in biofilms is difficult.
[00071 Even if an antibiotic reaches a biofllm, a large portion of the bacteria would be insensitive to the specific antibiotic as bacteria in a bioflim occupied a spectrum of physiological state from rapid growing to dormant. The dormant bacteria are not vulnerable to the antibiotic. Later, these dormant bacteria can quickly renew the biofilm. Low oxygen concentration in the biofllm also protects the bacteria from some antibiotics.
[00081 The CDC claims that 65% of bacterial infections that are treated by physicians develop biofilm. Biofilm have been implicated in chronic infections. Most notable among them is staphylococcus aureus especially the methicillin resistant variety, staphylococcus epidermis and pseudomonas aeruginosa. Topical glycerin can treat biofilm in the mouth such as halitosis.
[0010] A 66 year old female developed cellulitis and an open ulcer on her leg. This was treated by oral antibiotics and was also treated at an outpatient wound care center. When the outpatient care was not successful she was admitted to the hospital for intravenous antibiotics. After 3 weeks there was no sign of improvement and the ulcer was enlarging. At this stage the ulcer measured 3 cm by I V2 cm in size and there was surrounding redness suggestive of inflammation. She was then given intravenous glycerin. The intravenous glycerin was given as a solution of 3% glycerin and 3% amino acids. This is currently the only commercially available source of intravenous glycerin. She was given the infusion at a rate of 80 cubic centimeters (cc) per hour. At the end of 48 hours there was evidence of healing in the ulcer. During these 48 hours she was continued on intravenous antibiotics.
After 72 hours the patient was discharged home on oral antibiotics. When she was re-examined 3 weeks later there was no evidence of the ulcer and the surrounding inflammation that was caused by cellulitis had totally cleared. Ulcers such as this patient had develop bacterial biofilm and can havc incrcascd resistance to antibiotics that at times cause the antibiotics to be ineffective.
SUMMARY OF THE INVENTION
[001 1] A method is disclosed comprising the administration of intravenous normal saline solution containing glycerin and amino acids to prevent or inhibit internal biofilm formation by bacteria.
[0012] In some embodiments, the concentration of glycerin in the normal saline solution is approximately 3%.
[0013] In some embodiments, the concentration of amino acids in the normal saline solution is approximately 3%.
[0014] In some embodiments, the intravenous solution is administered for 48 hours at 80 cc/hour.
[0015] In some embodiments, the normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is infused into an infected body cavity.
[0016] In some embodiments, the bacterial infection comprises methicil lin resistant staphylococcus aurcus.
[0017] In some embodiments, the bacterial infection comprises staphylococcus epidermis.
[001 8] In some embodiments, the bacterial infection comprises pseudomonas aeruginosa.
[0019] In some embodiments, the infected body cavity is a pleural cavity.
[0020] In somc embodiments, thc infcctcd body cavity is a pcritoncal cavity.
[0021] In some embodiments, approximately 500 cc of the normal saline solution comprising a ccrtain pcrccntagc concentration by volume of glycerin and a ccrtain percentage by volumc of an amino acid solution is infrised into an infected body cavity.
[00221 In some embodiments, greater than 500 cc of the normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is infused into an infected body cavity.
[00231 Also disclosed is a method of optimizing therapeutic efficacy for treatment of a bacterial infection within a body cavity comprising administering a normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution.
DETAILED DESCRIPTION OF TUE INVENTION
[00241 Glycerin is a simple polyol compound. Tons of it is produced annually in the United States and Europe. It is made from animal fats and vegetable oils. Only one company in the United States makes a product that is sterile and used for intravenous administration. It has been used since 1976 as a non-glycemic source of carbohydrates as a source of nutrition in patients who are unable to process food via the gastrointestinal tract. It is remarkable for its safety profile and is free of allergic reactions. It is generally infused at a 3% concentration at a rate of 80-100 milliliters per hour. Those with heart failure and kidney failure may need a slower rate of infusion. As in the case outlined here it can diffuse a bacterial biofllm.
[00251 Glycerin can assist antibiotics and the immune system in conquering bacteria biofllm.
In this capacity it can reduce the ever-occurring resistance of bacteria to antibiotics. Cavity spaces such as the pleural cavity and the peritoncal cavity can develop infections with biofllms. Infusing these cavities with the 3% solution of Glycerin would help breakdown these biofllms. For example, haifa liter of the solution would be infused into a pleural cavity.
A greater amount could be infused into the pcritoncal cavity.
[0026j Embodiments are directed to a method of treating a biofllm-associated infection in a subjcct comprising administering via an intravenous connection to the subject a normal saline solutioll comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution.
[0027] In some embodiments, the concentration of glycerin in the normal saline solution is approximately 3%.
[0028j In some embodiments, the concentration of amino acids in the normal saline solution is approximately 3%.
[0029j In some embodiments, the intravenous solution is administered for 48 hours at 80 cc/hour.
[0030j In some embodiments, the normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is infused into an infcctcd body cavity.
[00311 In somc cmbodimcnts, the infusion occurs via intracavernous administration.
[0032] In some embodiments, the bacterial infection comprises methicillin resistant staphylococcus aurcus.
[0033j In some embodiments, the bacterial infection comprises staphylococcus epidermis.
[0034] In some embodiments, the bacterial infection comprises pseudomonas aeruginosa.
[00351 In somc cmbodimcnts, the infected body cavity is a plcural cavity.
[00361 In somc cmbodimcnts, the infected body cavity is a peritoncal cavity.
[0037j A concentration higher than 3% of glycerin may be more effective.
[0038] Brand names include Procalamine from B. Braun Medical Inc. [00391 ProcalAmine® (3% Amino Acid and 3% Glycerin Injcction with Electrolytes) is a sterile, nonpyrogenic, moderately hypertonic intravenous injection containing crystalline amino acids, a nonprotein energy substrate and maintenance electrolytes.
[00401 A 1000 mL unit provides a total of 29 g of protein equivalent (4.6 g N) and 130 nonprotein calories.
[00411 Ad! amino acids designated USP are the "L"-isomer with the exception of G!ycine LJSP which does not have an isomer.
[0042] Table 1 provides the component weights per 100 mL.
TABLE I
Nonprotein energy source: Glycerin USP (glycerol) 3.0 g Essential amino acids Isoleucine USP 0.21 g Leucine (iSP 0.27 g Lysine (as Lysine Acetate (iSP 0.31 g) 0.22 g MethionineUSP 0.16 g Phenylalanine USP 0.17 g Threonine USP 0.12 g Tryptophan LiSP 0.046 g Valine USP 0.20 g Nonessential amino acids Alanine USP 0.21 g Glycine USP 0.42 g Arginine (iSP 0.29 g Histidine (iSP 0.085 g Pro!ine USP 0.34 g Scrinc (iSP 0.18 g Cysteine (as Cysteine HCIH2O USP <0.020) <0.014 g Sodium Acetate3H2O USP 0.20 g Magnesium Acetate*4H20 0.054 g Calcium AcetateH2O 0.026 g Sodium Chloride (iSP 0.12 g Potassium Chloride LISP 0.15 g Phosphoric Acid NF 0.04 1 g Potassium Metabisulfite NF (as an antioxidant) <0.05 g Water for!njection LiSP QS ph adjusted with Glacial Acetic Acid LiSP ph 6.8 (6.5-7.0) Calculated Osmolarity 735 mOsmol/liter [0043] These descriptions and drawings are embodiments and teachings of the present invention. Al! variations are within the spirit and scope of the present invention. This disclosure is not to be considered as limiting the present invention to only the embodiments illustrated.

Claims (18)

  1. CLAIMSWhat is claimed is: 1. A normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution, for use in treating a biofilm-associated infection in a subject wherein the solution is administered via an intravenous connection to the subject.
  2. 2. The solution for use according to claim I wherein the certain percentage concentration by volume of glycerin in the normal saline solution is approximately 3%.
  3. 3. The solution for use according to claim I wherein the certain percentage conccntration by volume of glycerin of amino acids in the normal saline solution is approximately 3%.
  4. 4. The solution for use according to claim 1 wherein the normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is administered for 48 hours at 80 cc/hour.
  5. 5. The solution for use according to claim I wherein the certain percentage concentration by volume of glycerin in the normal saline solution is greater than 3%.
  6. 6. The solution for use according to claim 1 wherein the biofilm-associated infection comprises methieillin resistant staphylococcus aureus.
  7. 7. The solution for use according to claim 1 wherein the biofilm-associated infection comprises staphylococcus epidermis.
  8. 8. The solution for use according to claim I wherein the biofllm-associated infection comprises pseudomonas aeruginosa.
  9. 9. A normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution, for use in optimizing therapeutic efficacy for treatment of a bacterial infection within a body cavity.
  10. 10. The solution for use according to claim 9 wherein the normal saline solution is administered via intravenous connection.
  11. 11. The solution for use according to claim 9 wherein the normal saline solution is infused via intracavernous administration.
  12. 12. The solution for use according to claim 9 wherein the bacterial infection comprises methicillin resistant staphylococcus aurcus.
  13. 13. The solution for use according to claim 9 wherein the bacterial infection comprises staphy'ococcus epidermis.
  14. 14. The solution for use according to claim 9 wherein the bacterial infection comprises pscudomonas acruginosa.
  15. 15. The solution for use according to claim 9 wherein the body cavity is the pleural cavity.
  16. 16. The solution for use according to claim 9 wherein the body cavity is the peritoneal cavity.
  17. 17. The solution for use according to claim 9 wherein a volume of approximately 500 cc of the normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is infused into the infected body cavity.
  18. 18. The solution for usc according to claim 9 wherein a volume greater than 500 cc ofthc normal saline solution comprising a certain percentage concentration by volume of glycerin and a certain percentage by volume of an amino acid solution is inffiscd into the infected body cavity.
GB1318577.2A 2013-06-06 2013-10-21 A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin Withdrawn GB2514863A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/912,060 US9549904B2 (en) 2012-06-06 2013-06-06 Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin

Publications (2)

Publication Number Publication Date
GB201318577D0 GB201318577D0 (en) 2013-12-04
GB2514863A true GB2514863A (en) 2014-12-10

Family

ID=49727096

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1318577.2A Withdrawn GB2514863A (en) 2013-06-06 2013-10-21 A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin

Country Status (3)

Country Link
CA (1) CA2829731A1 (en)
DE (1) DE102013020916A1 (en)
GB (1) GB2514863A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242657A4 (en) * 2015-01-06 2018-09-12 Bryan, Thomas Benedict Methods of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11382885B2 (en) 2017-06-07 2022-07-12 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263115A1 (en) 2016-06-30 2018-01-03 Technische Hochschule Mittelhessen Invention relating to an agent combating pseudomonas aeruginosa

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123319A1 (en) * 2011-11-15 2013-05-16 Thomas Benedict Bryan Medthod of Treating a systemic inflammatory disorder and damaged internal tissues
US20140018438A1 (en) * 2012-06-06 2014-01-16 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123319A1 (en) * 2011-11-15 2013-05-16 Thomas Benedict Bryan Medthod of Treating a systemic inflammatory disorder and damaged internal tissues
US20140018438A1 (en) * 2012-06-06 2014-01-16 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242657A4 (en) * 2015-01-06 2018-09-12 Bryan, Thomas Benedict Methods of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11382885B2 (en) 2017-06-07 2022-07-12 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US11779559B2 (en) 2017-06-07 2023-10-10 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Also Published As

Publication number Publication date
DE102013020916A1 (en) 2014-12-11
GB201318577D0 (en) 2013-12-04
CA2829731A1 (en) 2014-12-06

Similar Documents

Publication Publication Date Title
US9549904B2 (en) Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
AU2011207398B2 (en) Antimicrobial agent comprising peroxide, alcohol and chelating agent
Cervantes‐Sánchez et al. Syringe pressure irrigation of subdermic tissue after appendectomy to decrease the incidence of postoperative wound infection
CN105142728B (en) Compositions and methods for treating surface wounds
ES2526640T3 (en) Compositions to break and inhibit the reconstitution of the wound biofilm
KR20170018852A (en) Topical compositions and methods for treating wounds
GB2514863A (en) A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
BR112020003001A2 (en) topical semi-solid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
JP6104390B2 (en) Improved wound healing composition comprising microspheres
US9480669B2 (en) Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion
Di Paolo et al. Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO)
US20230338296A1 (en) Devices and methods for delivery of oxygen to a wound
US10456416B2 (en) Compositions and methods of treating microbes
RU2418597C1 (en) Method of treating chronic tonsillitis
RU2602692C1 (en) Method of treating chronic pharyngitis
RU2486892C1 (en) Method of lymphotropic therapy in case of orthodontal abscesses in rabbits
RU2659199C1 (en) Medicinal product in complex therapy of chronic cystitis and method of complex therapy of chronic cystitis
CN117653736A (en) Tissue repair in-situ gel drop and preparation method thereof
US20150190455A1 (en) Herpes Treatment

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)